Home / Resource Library / Open label, phase 2 study of blinatumomab after frontline R-chemotherapy in adults with newly diagnosed, high risk DLBCL

Open label, phase 2 study of blinatumomab after frontline R-chemotherapy in adults with newly diagnosed, high risk DLBCL

Results of a study investigating blinatumomab after first line chemoimmunotherapy in diffuse large b-cell lymphoma.